Literature DB >> 24951331

Syntheses, neural protective activities, and inhibition of glycogen synthase kinase-3β of substituted quinolines.

Jianyu Lu1, Izumi Maezawa2, Sahani Weerasekara1, Ramazan Erenler1, Tuyen D T Nguyen1, James Nguyen1, Luxi Z Swisher1, Jun Li1, Lee-Way Jin2, Alok Ranjan3, Sanjay K Srivastava3, Duy H Hua4.   

Abstract

A new series of fifteen 5-, 6-, and 8-appended 4-methylquinolines were synthesized and evaluated for their neural protective activities. Selected compounds were further examined for their inhibition of glycogen synthase kinase-3β (GSK-3β) and protein kinase C (PKC). Two most potent analogs, compounds 3 and 10, show nanomolar protective activities in amyloid β-induced MC65 cells and enzymatic inhibitory activities against GSK-3β, but poor PKC inhibitory activities. Using normal mouse model, the distribution of the most potent analog 3 in various tissues and possible toxic effects in the locomotors and inhibition of liver transaminases activities were carried out. No apparent decline of locomotor activity and no inhibition of liver transaminases were found. The compound appears to be safe for long-term use in Alzheimer's disease mouse model.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid β; Glycogen synthase kinase-3β; Neural protective activity; Protein kinase C; Quinolines

Mesh:

Substances:

Year:  2014        PMID: 24951331      PMCID: PMC4110911          DOI: 10.1016/j.bmcl.2014.05.085

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  27 in total

1.  Studies in the quinoline series; the preparation of some 8-(omega-alkylaminoalkylamino)-quinolines.

Authors:  K N CAMPBELL; A H SOMMERS
Journal:  J Am Chem Soc       Date:  1946-08       Impact factor: 15.419

Review 2.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

3.  Inhibition of Acyl-CoA: cholesterol acyltransferase (ACAT), overexpression of cholesterol transporter gene, and protection of amyloid β (Aβ) oligomers-induced neuronal cell death by tricyclic pyrone molecules.

Authors:  Laxman Pokhrel; Izumi Maezawa; Thi D T Nguyen; Kyeong-Ok Chang; Lee-Way Jin; Duy H Hua
Journal:  J Med Chem       Date:  2012-10-05       Impact factor: 7.446

4.  Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.

Authors:  Chuang Guo; Tao Wang; Wei Zheng; Zhong-Yan Shan; Wei-Ping Teng; Zhan-You Wang
Journal:  Neurobiol Aging       Date:  2012-06-19       Impact factor: 4.673

5.  Phosphorylation of Activation Transcription Factor-2 at Serine 121 by Protein Kinase C Controls c-Jun-mediated Activation of Transcription.

Authors:  Takahito Yamasaki; Akinori Takahashi; Jianzhi Pan; Naoto Yamaguchi; Kazunari K Yokoyama
Journal:  J Biol Chem       Date:  2009-01-28       Impact factor: 5.157

6.  Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo.

Authors:  Hyun-Seok Hong; Sandeep Rana; Lydia Barrigan; Aibin Shi; Yi Zhang; Feimeng Zhou; Lee-Way Jin; Duy H Hua
Journal:  J Neurochem       Date:  2009-02       Impact factor: 5.372

7.  Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice.

Authors:  Qiu-Lan Ma; Xiaohong Zuo; Fusheng Yang; Oliver J Ubeda; Dana J Gant; Mher Alaverdyan; Edmond Teng; Shuxin Hu; Ping-Ping Chen; Panchanan Maiti; Bruce Teter; Greg M Cole; Sally A Frautschy
Journal:  J Biol Chem       Date:  2012-12-21       Impact factor: 5.157

8.  Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.

Authors:  Anna M Lilja; Yu Luo; Qian-sheng Yu; Jennie Röjdner; Yazhou Li; Ann M Marini; Amelia Marutle; Agneta Nordberg; Nigel H Greig
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

9.  Bioavailability and efficacy of a gap junction enhancer (PQ7) in a mouse mammary tumor model.

Authors:  Stephanie N Shishido; Keshar Prasain; Amanda Beck; Thi D T Nguyen; Duy H Hua; Thu Annelise Nguyen
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

10.  Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.

Authors:  Sefika Ozcelik; Graham Fraser; Perrine Castets; Véronique Schaeffer; Zhiva Skachokova; Karin Breu; Florence Clavaguera; Michael Sinnreich; Ludwig Kappos; Michel Goedert; Markus Tolnay; David Theo Winkler
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.